Recurrence of melanoma following T cell treatment: Continued antigen expression in a tumor that evades T cell recruitment

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 396-406

  Straetemans, Trudy ^a   Berrevoets, Cor ^a   Coccoris, Miriam ^a   Treffers Westerlaken, Elike ^a   Wijers, Rebecca ^a   Cole, David K ^b   Dardalhon, Valerie ^c   Sewell, Andrew K ^b   Taylor, Naomi ^c   Verweij, Jaap ^a   Debets, Reno ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; IMMUNE RESPONSE GENE; IMMUNOGENICITY; LYMPHOCYTE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MONOCYTE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN METHYLATION; T LYMPHOCYTE; THERAPY EFFECT; TUMOR ESCAPE; TUMOR REGRESSION; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DISEASE MODEL; DNA METHYLATION; EXPERIMENTAL MELANOMA; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; RECURRENT DISEASE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE;

MUS;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; T-LYMPHOCYTES;

EID: 84922234972     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.215     Document Type: Article

References (51)

1. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L., et al. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655
2. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP., et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357
3. Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S., et al. (2013). TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen T Cell Fitness and Sensitization of Tumor Milieu. Front Immunol 4: 363
4. Govers C, Sebestyén Z, Coccoris M, Willemsen RA and Debets R. (2010). T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med 16: 77-87
5. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E., et al. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence migration and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173
6. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J and Andreesen R. (2006). Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24: 5060-5069
7. Algarra I, Cabrera T and Garrido F. (2000). The HLA crossroad in tumor immunology. Hum Immunol 61: 65-73
8. Seliger B, Maeurer MJ and Ferrone S. (2000). Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464
9. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C., et al. (1996). Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98: 1633-1641
10. Khong HT, Wang QJ and Rosenberg SA. (2004). Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27: 184-190
11. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM., et al. (2011). Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19: 72-85
12. Ward PL, Koeppen HK, Hurteau T, Rowley DA and Schreiber H. (1990). Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 50: 3851-3858
13. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J., et al. (2012). Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209: 495-506
14. Springer TA. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314
15. Cooper D, Iqbal AJ, Gittens BR, Cervone C and Perretti M. (2012). The effect of galectins on leukocyte trafficking in inflammation: sweet or sour?. Ann N Y Acad Sci 1253: 181-192
16. Gerke V and Moss SE. (2002). Annexins: from structure to function. Physiol Rev 82: 331-371
17. Yáñez-Mó, M, Barreiro O, Gordon-Alonso M, Sala-Valdés M and Sánchez-Madrid F. (2009). Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19: 434-446
18. Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E and Eisenbach L. (2008). Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res 68: 3450-3457
19. Khong HT and Restifo NP. (2002). Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol 3: 999-1005
20. DuPage M, Mazumdar C, Schmidt LM, Cheung AF and Jacks T. (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409
21. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ., et al. (2012). Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404
22. Maryanski JL, Marchand M, Uyttenhove C and Boon T. (1983). Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int J Cancer 31: 119-123
23. Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B., et al. (2011). Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71: 1253-1262
24. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R., et al. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703
25. Spiotto MT, Rowley DA and Schreiber H. (2004). Bystander elimination of antigen loss variants in established tumors. Nat Med 10: 294-298
26. Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H., et al. (2009). Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen crosspresented on stromal cells. J Immunol 183: 1828-1837
27. Schreiber RD, Old LJ and Smyth MJ. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570
28. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha, TT., et al. (2013). Upregulation of PD-L1, IDO and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5: 200ra116
29. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M., et al. (2012). Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490: 412-416
30. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C., et al. (2006). Type density and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964
31. Kalialis LV, Drzewiecki KT and Klyver H. (2009). Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19: 275-282
32. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G., et al. (2003). Intratumoral T cells recurrence and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213
33. Lee HW, Choi HJ, Ha, SJ, Lee KT and Kwon YG. (2013). Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835: 170-179
34. Rahir G and Moser M. (2012). Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 61: 751-759
35. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C., et al. (2011). Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma favoring T-cell infiltration and tumor control. Cancer Res 71: 6997-7009
36. Sperandio M, Gleissner CA and Ley K. (2009). Glycosylation in immune cell trafficking. Immunol Rev 230: 97-113
37. Nakahara S and Raz A. (2008). Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 8: 22-36
38. Romanska HM and Berditchevski F. (2011). Tetraspanins in human epithelial malignancies. J Pathol 223: 4-14
39. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM., et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343
40. Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J and Vile R. (2012). Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 23: 1054-1064
41. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S and Debets R. (2010). T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther 10: 547-562
42. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B., et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31: e439-e442
43. Fu, H, Kishore M, Gittens B, Wang G, Coe D, Komarowska I., et al. (2014). Selfrecognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation. Nat Commun 5: 3436
44. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS., et al. (2014). Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20: 607-615
45. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A., et al. (2012). Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122: 899-910
46. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
47. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R., et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144
48. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP., et al. (2011). Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3: 80ra34
49. Porter DL, Levine BL, Kalos M, Bagg A and June CH. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733
50. Gattinoni L, Klebanoff CA and Restifo NP. (2012). Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12: 671-684
51. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M., et al. (2014). Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 41: 116-126